



(12) Translation of
European patent specification

(11) NO/EP 3389699 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/28 (2006.01)
A61K 39/395 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.07.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.05.01
(86)	European Application Nr.	16876612.9
(86)	European Filing Date	2016.12.14
(87)	The European Application's Publication Date	2018.10.24
(30)	Priority	2015.12.15, US, 201562267735 P 2016.03.16, US, 201662309169 P 2016.07.06, US, 201662359036 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	OncoC4, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA
(72)	Inventor	LIU, Yang, 502 E Street NE, Washington, District of Columbia 20002, USA ZHENG, Pan, 502 E Street NE, Washington, District of Columbia 20002, USA DEVENPORT, Martin, 614 Still Creek Lane, Gaithersburg, Maryland 20878, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	CHIMERIC AND HUMANIZED ANTI-HUMAN CTLA4 MONOCLONAL ANTIBODIES AND USES THEREOF
(56)	References Cited:	CN-A- 101 628 940 WO-A1-2012/120125 US-A1- 2013 136 749 US-A1- 2006 228 299 US-B1- 7 923 221 WO-A1-2014/089113 MAY KENNETH F JR ET AL: "Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 3, 1 February 2005 (2005-02-01), pages 1114-1120, XP002500693, ISSN: 0006- 4971, DOI: 10.1182/BLOOD-2004-07-2561

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Anti-CTLA4-antistoff i stand til å binde humant CTLA4, omfattende: en tung kjede omfattende aminosyresekvensen angitt i SEKV. ID NR.: 64, en lett kjede omfattende aminosyresekvensen angitt i SEKV. ID NR.: 71 og en IgG1-Fc-region omfattende sekvensen angitt i SEKV. ID NR.: 4.

5

2. Farmasøytisk sammensetning omfattende en terapeutisk virksom mengde av anti-CTLA4-antistoffet ifølge krav 1, og en fysiologisk akseptabel bærer eller tilsetning.

3. Farmasøytisk sammensetning ifølge krav 2 for bruk ved behandling av kreft hos et individ.

10

4. Farmasøytisk sammensetning for bruk ifølge krav 3, videre omfattende bruk av et ytterligere middel valgt fra gruppen bestående av anti-PD-1- og anti-4-1BB-antistoffer.

5. Farmasøytisk sammensetning for bruk ifølge krav 4, hvor anti-PD-1- eller anti-4-1BB-antistoffene og anti-CTLA4-antistoffet kombineres i ett enkelt molekyl som bispesifikke antistoffer.

15